Cogent Biosciences Inc
Could not find a ticker for this position, may be a filing error
A clinical-stage biotechnology company in Waltham, Massachusetts, developing precision therapies for genetically defined diseases. Its lead drug candidate, bezuclastinib, targets the KIT D816V mutation that drives systemic mastocytosis, a rare disease marked by abnormal buildup of mast cells. The company took its name in 2020 when Unum Therapeutics combined with a private firm also called Cogent Biosciences — "cogent" meaning clear, logical, and convincing.
1.625% Convertible Senior Notes due 2031
No filing summaries or text available for this security.